Lili Wang
Honorary Researcher
I am a senior immunologist and strategic R&D leader with extensive experience across biotech, pharma, and academia, specialising in cell therapy (TIL/TCR-T), immuno-oncology, translational science, and the integration of wet-lab biology with AI-enabled discovery. My work spans early discovery through to translational studies, clinical trial support, manufacturing considerations, and investor-facing strategy.
I have led wet-lab immunology pipelines supporting cell therapy and immuno-oncology programmes, including the development and optimisation of assays, workflows, and translational datasets. In addition, I have contributed as part of multidisciplinary teams working on engineered viral and RNA-based immunotherapies, collaborating closely with discovery scientists, computational biologists, and translational experts to advance therapeutic candidates.
Earlier in my career, I contributed to national pandemic preparedness efforts by leading the T-cell immunity component of a 2,500-participant UK cohort study investigating immune protection against emerging influenza strains. This work was conducted in collaboration with epidemiologists at UCL, virologists at the UK public health agency (formerly the Health Protection Agency), and the MRC research nurse network. I also led the T-cell immunology workstream of a Novartis-funded paediatric influenza vaccine trial, which explored the use of an adjuvant to enhance vaccine-induced immunity and improve protection in children.
As a biotech co-founder (Bioarchitech Ltd.) and scientific advisor, I bring an entrepreneurial mindset and experience in shaping scientific strategy, securing funding, building partnerships, working with Boards/SABs, and supporting due diligence and licensing processes. I enjoy leading and mentoring scientific teams and working across disciplines to accelerate innovative therapies toward the clinic.
I am driven by the challenge of uniting deep immunology, translational science, and emerging discovery technologies to advance impactful treatments and strengthen preparedness for future health threats.
Expertise: Cell Therapy (TIL/TCR-T) • Immuno-Oncology • Wet-Lab Immunology Leadership • Translational Science • Viral & RNA Therapeutics (cross-functional collaboration) • AI-Enabled Discovery • Pipeline Design • Programme Leadership • Due Diligence • Scientific Strategy • Early-Stage Biotech • Team Development